AtheroGenics files for bankruptcy

AtheroGenics (NASDAQ:AGIX) filed for Chapter 11 bankruptcy and hired Merriman Curhan Ford to assist with the sale of the company or its assets. AtheroGenics' lead compound is AGI-1067, a small molecule that blocks vascular cell adhesion molecule-1 (VCAM-1) expression. In July, the company reported that the compound met the primary endpoint in the Phase III ANDES trial to treat Type II diabetes (See BioCentury Extra, Thursday, July 31, 2008). ...